BIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Rad Laboratories Inc (BIO) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock is facing challenges in its growth and margin-driving segments, particularly in process chromatography and the China diagnostics market. Additionally, financial performance has been weak, with significant declines in net income and EPS. While hedge funds have shown interest, there are no strong technical or proprietary trading signals to suggest immediate upside potential. For a long-term investor, it may be prudent to wait for clearer signs of recovery or improvement in fundamentals before committing capital.
The MACD is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 65.675, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 284.03, with resistance at 294.393 and support at 273.666. Overall, the technical indicators suggest a neutral stance.
Hedge funds are significantly increasing their positions in the stock, with a 333305.80% increase in buying activity over the last quarter.
Analysts have downgraded the stock, citing challenges in the process chromatography business and uncertainties in the China diagnostics market. Financial performance in Q4 2025 was weak, with significant declines in net income and EPS. No recent news or Congress trading data to provide additional positive sentiment.
In Q4 2025, revenue increased by 3.85% YoY to $693.2M. However, net income dropped by -200.59% YoY to $720M, and EPS fell by -204.22% YoY to 26.65. Gross margin also declined by -2.89% YoY to 49.74%, indicating deteriorating profitability.
Recent analyst ratings are negative. Citi downgraded the stock to Neutral with a reduced price target of $300, citing no recovery path for key growth areas. Wells Fargo and UBS also lowered their price targets, highlighting weak guidance and margin challenges.
